Restructuring Edition: BioMarin’s layoffs are associated with strategic shifts announced during its second quarter update. Also, Repare reduced its workforce by 25% as it focused in on clinical-stage programs and Aadi cut 80% of its R&D team to conserve cash after a clinical trial failure. 

Plus deals involving AstraZeneca/Conduit, Recursion/Exscientia, G1/Pharmacosmos, Sanofi/Vir, Passage Bio/GEMMA and Lupin/Evofem. Also including deals in brief.

Unilabs and C2N Diagnostics signed a multi-year agreement that will expand access to C2N’s Alzheimer’s tests in Europe and other countries.

Only three of the 10 new therapies approved by the US FDA also have been approved in the European Union, while both of the EU gene therapy approvals followed FDA clearance, a Pink Sheet analysis shows.